Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy

IgA nephropathy (IgAN) is an important cause of ESKD for which there are no approved therapies. A challenge for evaluating treatments for IgAN is the usual long time course for progression to ESKD. The aim of this Kidney Health Initiative project was to identify surrogate end points that could serve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Clin J Am Soc Nephrol
Autors principals: Thompson, Aliza, Carroll, Kevin, A. Inker, Lesley, Floege, Jürgen, Perkovic, Vlado, Boyer-Suavet, Sonia, W. Major, Rupert, I. Schimpf, Judith, Barratt, Jonathan, Cattran, Daniel C., S. Gillespie, Barbara, Kausz, Annamaria, W. Mercer, Alex, Reich, Heather N., H. Rovin, Brad, West, Melissa, Nachman, Patrick H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Nephrology 2019
Matèries:
Feature
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6419287/
https://ncbi.nlm.nih.gov/pubmed/30635299
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2215/CJN.08600718
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars